Biosign off to the races, enters multi-year technical partnership with AIM
Autosport
TORONTO, May 18 /CNW/ - Biosign Technologies Inc. (CNSX:BIO) ("Biosign" or the "Company") and AIM Autosport ("AIM") announced today a multi-year technical partnership for enhancing driver performance and safety in the motor sport industry.
Modern racing demands top conditioning of car and driver. Fine tuning the vehicle involves advanced test and diagnostic technologies. Under this agreement, Biosign will address the other side of the equation - fine tuning the driver's health.
Fine tuning a driver's response to stress requires precise observation and detailed analysis of key physiological variables such as blood pressure, heart rate, and blood glucose. Measuring and analyzing these variables in people exposed to significant g forces and temperatures exceeding 100F provides unique opportunities for improving and expanding Biosign's health monitoring services to include diet, endurance, heat, and exhaustion management.
"In the years AIM has been racing, driver performance has always been a key issue in our success on the race track," commented AIM's Team Principal Ian Willis. "Once we entered the field of endurance racing, we had to take note of the many parameters that can affect the driver's performance under adverse conditions including heat, dehydration, physical stress and fatigue. We have a number of systems in place to address those issues but our partnership with Biosign will allow AIM to enhance the driver's condition before, during and following on-track sessions. With Biosign, we now have the monitoring abilities and backup data to provide us a better understanding of the stress experienced by our drivers, which will help us compete against some of the best race drivers in the world."
Biosign's UFIT health monitoring system will be used initially to address fitness and health evaluation issues. Radu Leca, Biosign's president, noted: "The focus on preventing injuries and ill health in sports will boost our profile in this very important area of health care. We are delighted that AIM chose us to test, validate, and provide advanced health monitoring services, using the experience and solutions we already have in this arena."
Under the partnership, AIM will be marketing and creating brand awareness for Biosign in one of the fastest growing sports in America. Biosign branding will be prominent on the AIM No. 61 Ford Riley as it competes in the "GRAND-AM Rolex Sports Car Series presented by Crown Royal Cask No. 16". The first race featuring the Biosign branding is scheduled for May 31st, 2010 at Lime Rock Park in Lakeville, Connecticut and can be seen on SPEED TV live at 2:00pm (ET).
About Biosign Technologies Inc.
Biosign provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT(R) medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign please visit www.biosign.com
About AIM Autosport:
Established in 1995, AIM Autosport's mandate is to identify, train and manage emerging Motorsport talent. AIM has provided many young drivers with a solid foundation on which to build a career in professional racing. The success of the AIM driver development programs has been achieved through the dedication of our employees and the ongoing support of our commercial and technical partners. Away from the track, AIM Autosport serves the needs of the racing community with a purpose-built preparation shop situated in the Toronto suburb of Woodbridge, Ontario. AIM fields the No. 61 Ford Riley with drivers Mark Wilkins and Burt Frisselle in the GRAND-AM Rolex Sports Car Series. The team also competes in the Star Madza Championship presented by Goodyear and the Cooper Tires presents the USF2000 Series powered by Mazda. Both series are an integral part of the new Road to Indy driver development series. AIM won the 2008 Star Mazda Championship with driver John Edwards. For more information please visit www.aimautosport.com
About GRAND-AM Road Racing
GRAND-AM Road Racing, which was founded in 1999, revolutionized major league sports car road racing in North America. GRAND-AM was acquired by NASCAR Holdings in late 2008 and operates now as one organization, with resources such as marketing, research and public relations fully integrated into the NASCAR framework. GRAND-AM Road Racing has the largest sports car fan base in the United States, with nearly 20 million adults, and has also had the highest percentage growth of any major motorsports series on television over the past five years. GRAND-AM sanctions the Rolex Sports Car Series presented by Crown Royal Cask No. 16 and the Continental Tire Sports Car Challenge. The Rolex Series and Continental Tire Sports Car Challenge deliver professional sports car racing to key markets throughout North America in addition to being televised in the U.S. and Canada on SPEED and distributed globally through ESPN International.
GRAND-AM Road Racing showcases emerging and legendary drivers from around the globe and thoroughbred racing machines from the industry's leading constructors and the world's top automobile manufacturers. For more information please visit www.grand-am.com
The CNSX has neither approved nor disapproved the contents of this press release.
For further information: Radu Leca, President & CEO, Biosign Technologies Inc., Phone: (416) 218-9800 ext. 234, Email: [email protected]
Share this article